Phase 1 N=38 Relative Bioavailability of Pimasertib in Cancer Patients
Neoplasms
Primary: Maximum Observed Plasma Concentration (Cmax) — 254.6; 314.1 nanogram per milliliter (ng/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=122 Combined Pharmacotherapy for Cannabis Dependency
Cannabis Dependence · Marijuana Dependence
Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants
N/A N=12 Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
Tobacco Use Disorder
Primary: Cigarette Choice After 3 Day Abstinence — 2.50; 3.67 number of cigarette choices (0-6)
N/A N=90 Analgesia After Total Hip Arthroplasty: Peri-Articular Injection Versus Epidural Patient Controlled Analgesia (PCA)
Osteoarthritis
Primary: Time Until Patient is Ready for Discharge — 2.4; 2.3 days
Phase 4 N=14 A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
Chronic Kidney Disease · Poorly-Controlled Hypertension
Primary: Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks — -10.5 mmHg — p=0.01
N/A N=43 A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Who Remained on Tocilizumab Treatment at 6 Months After Treatment Initiation — 63 percentage of participants
Phase 3 N=262 Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
HIV Infections · Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) — 34.8; 25.4 percentage of participants
N/A N=40 Effect of Steroids on Thrombosis (Blood Clot Formation) and Inflammation in Patients Undergoing Hip Surgery
Total Hip Replacement
Primary: Serum Prothrombin Fragment 1 and 2 (PF 1.2) — 334.15; 298.12; 778.33; 619.21 pmol/mL
Phase 2 N=17 A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B
Hemophilia B
Primary: Number of Subjects With Treatment-related Adverse Events — 0 participants
N/A N=428 Cardiovascular Intervention Improvement Telemedicine Study
Cardiovascular Disease · Hypertension · Diabetes
Primary: Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent) — 32.4; 31.6 % 10 yr Risk
Phase 2 N=8 Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency
Cholesterol Ester Storage Disease (CESD) · Lysosomal Acid Lipase Deficiency · LAL-Deficiency
Primary: Number Of Participants Reporting TEAEs And IARs — 8; 1; 2; 0 Participants
N/A N=2,343 PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population — 46.1; 78.0; 68.3; 43.0…
N/A N=24 A Open Study to Evaluate the Performance of Dressing on Subject With High Risk of Skin Breakdown
Critical Illness
Primary: Erythema (No/Yes) — 21; 3 participants
Phase 3 N=27 A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
Hemophilia B
Primary: Incremental Recovery Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product — 1.0114; 0.9506; 1.0600; 0.7379 (IU/dL)/(IU/kg)
Phase 3 N=18 A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
Hypogonadism · Hypogonadotropic Hypogonadism
Primary: Change From Baseline in Log-Transformed Testicular Volume at Week 52 — 2.3 Fold change